TRANSMURAL SYSTEMS LLC — Department of Health and Human Services SBIR Phase II: NHLBI
TRANSMURAL SYSTEMS LLC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,999,984, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code NHLBI links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $2,999,984
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NHLBI
- NAICS
- —
- Place of performance
- MA
- Period
- —
Description
Extra anatomic bypass or vascular shunts divert blood flow In congenital heart disease these surgical procedures are critical for management Children born with one functional ventricle or cardiac pumping chamber require two to three major cardiac surgery procedures for palliation The management goal is to divert systemic venous return deoxygenated blood from the heart directly to pulmonary artery circulation such that the single ventricle can pump oxygenated blood returning to the heart from the lungs to the body These multiple surgical procedures carry significant morbidity and mortality as well as incur substantial hospital costs secondary to lengthy hospital stays A minimally invasive transcatheter approach would revolutionize the management of these children with congenital heart disease No commercial alternatives exist for off label medical use Children born with single ventricle physiology represent of congenital heart disease diagnosed in childhood and have a birth incidence of approximately per In the United States this represents approximately children born each year The commercial market is small enough to discourage the early development costs of a transcatheter cavopulmonary bypass endograft There is a considerable unmet need for a purpose built cavopulmonary anastomosis device